We are live on ! Find out more
CANF icon

Can-Fite BioPharma American Depositary Shares
CANF

7 hedge funds and large institutions have $1.84M invested in Can-Fite BioPharma American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more capital inflows, than outflows

Capital inflows: $174K | Capital outflows: $72K

0.03% more ownership

Funds ownership: 0.48% → 0.5% (+0.03%)

30% less funds holding

Funds holding: 10 → 7 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
7
Holders Change
-3
Holders Change %
-30%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Meitav Investment House
Meitav Investment House
Israel
+$127K
2
Morgan Stanley
Morgan Stanley
New York
+$42.4K
3
UBS Group
UBS Group
Switzerland
+$3.86K

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$35K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$17K
3
Two Sigma Securities
Two Sigma Securities
New York
-$17K
4
IFP Advisors
IFP Advisors
Florida
-$3K

CANF Hedge Fund Activity: Q4 2018 in Review

7 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2018, worth a combined $1.84M — down 1.6% from $1.87M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CANF and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Meitav Investment House, adding an estimated $127K. The largest seller was Virtu Financial, exiting entirely with an estimated $35K sold.

  • 7 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2018, down from 10 in Q3 2018.
  • Funds reported $1.84M of Can-Fite BioPharma American Depositary Shares stock for Q4 2018, down 1.6% quarter-over-quarter.
  • 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2018 and 4 closed out, a net change of -3 holders.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2018 was Meitav Investment House, an estimated $127K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2018 was Virtu Financial, an estimated $35K sold.

Based on aggregated 13F filings for Q4 2018.